Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,918 questions · 5,537 findings · 1,803 reviews

No studies found 1,309 · 23.6%GRADE not reported 440 · 7.9%Very low 1,560 · 28.2%Low 1,292 · 23.3%Moderate 751 · 13.6%High 185 · 3.3%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings: aztreonam lysine for inhalation vs tobramycin

Adverse events: number of treatment‐related adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: aztreonam lysine for inhalation probably leads to higher adverse events: number of treatment‐related adverse events compared with tobramycin (moderate certainty).

1 finding from 1 review

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

Adverse events: any adverse event in the comparative phase · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: continuous cycles alternating aztreonam lysine… showed no clear difference in adverse events: any adverse event in the comparative phase compared with continuous cycles alternating placebo with tobramycin (low certainty).

1 finding from 1 review

Induced hypertension vs placebo or no intervention

Proportion of participants with ≥ 1 serious adverse events · people with acute subarachnoid haemorrhage

It is very uncertain whether induced hypertension changes proportion of participants with ≥ 1 serious adverse events compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Rivastigmine vs placebo

Serious adverse events (excluding death) at 24 to 26 weeks · vascular dementia and other vascular cognitive impairments

Rivastigmine showed no clear difference in serious adverse events (excluding death) at 24 to 26 weeks compared with placebo (low certainty).

1 finding from 1 review

Resin-based fissure sealant vs Fluoride varnish

Safety of sealants and fluoride varnishes (adverse events) · Children and adolescents (general population, aged under 20 years)
1 finding from 1 review

Azathioprine vs methotrexate

Adverse event causing death or study drug discontinuation · adults with renal vasculitis for maintenance therapy

Azathioprine showed no clear difference in adverse events causing death or study drug discontinuation compared with methotrexate (low certainty).

1 finding from 1 review

Intervention not reported

Adverse events ‐ Miscarriage№ of participants: 304(3 RCTs) · women with subfertility

The intervention showed no clear difference in adverse events ‐ Miscarriage№ of participants: 304(3 RCTs) (low certainty).

1 finding from 1 review

Antibiotic 1 vs antibiotic 2

Adverse events: nitrofurantoin (1) versus trimethoprim (2) · children with primarily normal renal tracts who have experienced at least one UTI

Antibiotic 1 may leads to higher adverse events: nitrofurantoin (1) versus trimethoprim (2) compared with antibiotic 2 (low certainty).

1 finding from 1 review